Below analyst target — what the screen found 2026-09-30

The screen returned 40 names today, with a notable concentration in the Manufacturing sector, where 30 of these companies reside¹˒²˒³˒⁴. This run highlights a specific subset of stocks trading well below their analyst consensus targets, indicating that there is significant disagreement between current market sentiment and analysts' expectations.

Tvardi Therapeutics (TVRD) has a market cap of $15.87M⁵, while Context Therapeutics (CNTX) comes in at $31.73M¹. Aligos Therapeutics (ALGS), with a market cap of $35.28M², and Connect Biopharma Holdings Limited (CNTB) at $67.07M³ also made the cut, along with Tenax Therapeutics ($68.30M) and iBio Inc. ($77.49M). Notably, all these companies are in the Manufacturing sector.

This screen identifies stocks trading well below analyst consensus targets, suggesting a potential disconnect between market price and analyst expectations. However, it is important to note that passing this test does not establish these as good buys or forecast future performance. The gap between current prices and target prices often widens due to falling stock prices rather than analysts turning bullish, and the screen merely highlights where there is disagreement without providing a verdict on what happens next.

In summary, while 40 companies met this criteria out of 3788 screened⁶˒⁷, passing this test does not guarantee future performance or investment suitability.